gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 19 Aug 2016.

Solute carrier family 4, anion exchanger, member 1a

Top mentioned proteins: CAN, BRAF, HAD, EGFR, ALK
Papers using RET antibodies
Usefulness of HBME-1, cytokeratin 19 and galectin-3 immunostaining in the diagnosis of thyroid malignancy
Alzohaili Opada et al., In Diagnostic Pathology, 2004
... Ret Oncoprotein3F81:40HIER EDTA BufferLeica Microsystems ...
Peptidase inhibitors improve recovery of substance P and calcitonin gene-related peptide release from rat spinal cord slices
Hingtgen Cynthia M et al., In Molecular Pain, 1995
... The Ret protein control, isolated from mice, was purchased from Santa Cruz Biotechnology.
unpublished data.
Awazu Shoji et al., In Biological Procedures Online, 1991
... L-Arginyl-L-tyrosine (retro-isomer of KTP, Ret-KTP) was purchased from Bachem Feinchemikalien AG (Switzerland).
Papers on RET
NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
Nikiforov et al., Bologna, Italy. In Cancer, Feb 2016
Six of 27 PTCs (22%) had ret proto-oncogene (RET) fusions (RET/PTC1, n = 5; RET/PTC3, n = 1); 2 tumors measured >2 cm and diffusely involved the thyroid, and 5 had lymphatic invasion, with vascular invasion in 2. Thirteen PTCs had the B-Raf proto-oncogene, serine/threonine kinase (BRAF) valine-to-glutamic acid mutation at position 600 (BRAF(V) (600E) ) (13 of 27 tumors; 48%), 11 measured <2 cm, and 6 had lymphatic invasion (46%), with vascular invasion in 3. Fusion oncogene tumors, compared with BRAF(V) (600E) PTCs, were associated with large size (mean, 2.2 cm vs 1.5 cm, respectively; P = .05),
HRAS mutation prevalence and associated expression patterns in pheochromocytoma.
Larsson et al., Stockholm, Sweden. In Genes Chromosomes Cancer, Feb 2016
HRAS mutated PPGL cluster together with NF1- and RET-mutated tumors associated with activation of kinase-signaling pathways.
Commentary to Gorelenkova Miller and Mieyal (2015): sulfhydryl-mediated redox signaling in inflammation: role in neurodegenerative diseases.
Yoshinaga et al., Nagoya, Japan. In Arch Toxicol, Feb 2016
Following their suggestions, we considered the correlation between sulfhydryl-mediated redox signaling and neurodegenerative diseases by focusing on RET proteins, a protein tyrosine kinases (PTKs) potentially sited upstream of the signal transduction cascade.
Role of Ingested Amino Acids and Protein in the Promotion of Resistance Exercise-Induced Muscle Protein Anabolism.
Rasmussen et al., Galveston, United States. In J Nutr, Feb 2016
These acute findings were critically tested via long-term exposure to RE training (RET) and protein/AA supplementation, and it was determined that a diminishing protein/AA supplement effect occurs over a prolonged exposure stimulus after exercise training.
Kinase Inhibitor Profiling Reveals Unexpected Opportunities to Inhibit Disease-Associated Mutant Kinases.
Peterson et al., Philadelphia, United States. In Cell Rep, Feb 2016
The results revealed lead compounds with activity against clinically important mutant kinases, including ALK, LRRK2, RET, and EGFR, as well as unexpected opportunities for repurposing FDA-approved kinase inhibitors as leads for additional indications.
Lenvatinib: Role in thyroid cancer and other solid tumors.
Habra et al., Houston, United States. In Cancer Treat Rev, Jan 2016
Lenvatinib targets vascular endothelial growth factor receptors 1-3 (VEGFR1-3), fibroblast growth factor receptors 1-4 (FGFR-1-4), RET, c-kit, and platelet-derived growth factor receptor α (PDGFRα).
Consensus on management of advanced medullary thyroid carcinoma on behalf of the Working Group of Thyroid Cancer of the Spanish Society of Endocrinology (SEEN) and the Spanish Task Force Group for Orphan and Infrequent Tumors (GETHI).
Galofré et al., Madrid, Spain. In Clin Transl Oncol, Jan 2016
It is a well-characterized neuroendocrine tumor arising from calcitonin-secreting C cells, and RET gene plays a central role on its pathogeny.
Emerging Biomarkers in Personalized Therapy of Lung Cancer.
Portier et al., Houston, United States. In Adv Exp Med Biol, Dec 2015
Other potential biomarkers which are currently undergoing clinical trials are RET, MET, HER2 and BRAF.
(Secondary) solid tumors in thyroid cancer patients treated with the multi-kinase inhibitor sorafenib may present diagnostic challenges.
Morreau et al., Leiden, Netherlands. In Bmc Cancer, Dec 2015
BACKGROUND: Sorafenib is an orally active multikinase tyrosine kinase inhibitor (TKI) that targets B-type Raf kinase (BRAF), vascular endothelial growth factor receptors (VEGFR) 1 and 2, and rearranged during transfection (RET), inducing anti-angiogenic and pro-apoptotic actions in a wide range of solid tumors.
Regulators of gut motility revealed by a gnotobiotic model of diet-microbiome interactions related to travel.
Gordon et al., Saint Louis, United States. In Cell, Oct 2015
Mice harboring a consortium of sequenced cultured bacterial strains from the Bangladeshi donor's microbiota and fed a Bangladeshi diet revealed that the commonly used cholekinetic spice, turmeric, affects gut motility through a mechanism that reflects bacterial BSH activity and Ret signaling in the ENS.
Mechanical induction of the tumorigenic β-catenin pathway by tumour growth pressure.
Farge et al., Paris, France. In Nature, Aug 2015
In the early stage of mouse colon tumour development in the Notch(+)Apc(+/1638N) mouse model, we observed mechanistic pressure stress in the non-tumorous epithelial cells caused by hyper-proliferative adjacent crypts overexpressing active Notch, which is associated with increased Ret and β-catenin signalling.
Quantification of Retinogenesis in 3D Cultures Reveals Epigenetic Memory and Higher Efficiency in iPSCs Derived from Rod Photoreceptors.
Dyer et al., Memphis, United States. In Cell Stem Cell, Aug 2015
To test this, we generated induced pluripotent stem cells (iPSCs) from murine rod photoreceptors (r-iPSCs) and scored their ability to make retinae by using a standardized quantitative protocol called STEM-RET.
Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Sherman et al., Aş Şanamayn, Syria. In N Engl J Med, Mar 2015
BACKGROUND: Lenvatinib, an oral inhibitor of vascular endothelial growth factor receptors 1, 2, and 3, fibroblast growth factor receptors 1 through 4, platelet-derived growth factor receptor α, RET, and KIT, showed clinical activity in a phase 2 study involving patients with differentiated thyroid cancer that was refractory to radioiodine (iodine-131).
Profile of nintedanib in the treatment of solid tumors: the evidence to date.
Schwarz et al., South Bend, United States. In Onco Targets Ther, 2014
Nintedanib (formally known as BIBF 1120) is a triple angiokinase inhibitor of VEGF, fibroblast growth factor, platelet-derived growth factor signaling with lesser activity against RET, Flt-3, and Src.
Anchored multiplex PCR for targeted next-generation sequencing.
Le et al., Boston, United States. In Nat Med, 2014
On the basis of our experience with performing AMP on 986 clinical FFPE samples, we show its potential as both a robust clinical assay and a powerful discovery tool, which we used to identify new therapeutically important gene fusions: ARHGEF2-NTRK1 and CHTOP-NTRK1 in glioblastoma, MSN-ROS1, TRIM4-BRAF, VAMP2-NRG1, TPM3-NTRK1 and RUFY2-RET in lung cancer, FGFR2-CREB5 in cholangiocarcinoma and PPL-NTRK1 in thyroid carcinoma.
Cell-specific mitotic defect and dyserythropoiesis associated with erythroid band 3 deficiency.
Zon et al., Boston, United States. In Nat Genet, 2003
evolutionarily conserved role for band 3 in erythroid-specific cell division and illustrates the concept of cell-specific adaptation for mitosis
share on facebooktweetadd +1mail to friends